Over the last year, I have had the good luck of being invited to give guest lectures for students at Columbia University, the University of Wisconsin and the University of Alabama. I was delighted when I was asked to return and lecture a new batch of students at the University of Wisconsin later this month. The topic of my lecture at each of these universities has been the use of Contingent Value Rights or CVRs in M&A.
We have discussed CVRs numerous times on InsideArbitrage, going back as much as nine years ago, when I wrote the article Tobira Therapeutics Hits The Jackpot and Provides a Nice Kicker and more recently in an article titled Roche to Buy Poseida, With a Potential $4 Lottery Ticket.